Current Stand on Systemic Therapy in Localized Soft Tissue Sarcomas: A Clinician's Perspective

References

• Cahlon O , BrennanMF, JiaX, QinLX, SingerS, AlektiarKM. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. Ann. Surg.255(2), 343–347 (2012).
   PubMed Web of Science ®Google Scholar
• Lawrence W , DoneganWL, NatarajanN, MettlinC, BeartR, WinchesterD. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann. Surg.205(4), 349–359 (1987).
   PubMed Web of Science ®Google Scholar
• Landuzzi L , ManaraMC, PazzagliaL, LolliniPL, ScotlandiK. Innovative breakthroughs for the treatment of advanced and metastatic synovial sarcoma. Cancers (Basel)15(15), 3887 (2023).
   PubMed Web of Science ®Google Scholar
• Fuchs JR , SchulteBC, FuchsJW, AgulnikM. Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma. Front. Oncol.13, 1123464 (2023).
   PubMedGoogle Scholar
• Brennan MF , AntonescuCR, MoracoN, SingerS. Lessons learned from the study of 10.000 patients with soft tissue sarcoma. Ann. Surg.260(3), 416 (2014).
   PubMed Web of Science ®Google Scholar
• Rupani A , HallinM, JonesRL, FisherC, ThwayK. Diagnostic differences in expert second-opinion consultation cases at a tertiary sarcoma center. Sarcoma2020, 9810170 (2020).
   PubMedGoogle Scholar
• Arbiser ZK , FolpeAL, WeissSW. Consultative (expert) second opinions in soft tissue pathology analysis of problem-prone diagnostic situations. Am. J. Clin. Pathol.116(4), 473–476 (2001).
   PubMed Web of Science ®Google Scholar
• Thway K , WangJ, MubakoT, FisherC. Histopathological diagnostic discrepancies in soft tissue tumours referred to a specialist centre: reassessment in the era of ancillary molecular diagnosis. Sarcoma2014, 686902 (2014).
   PubMedGoogle Scholar
• Wellauer H , StuderG, Bode-LesniewskaB, FuchsB. Time and accuracy to establish the diagnosis of soft tissue tumors: a comparative analysis from the Swiss Sarcoma Network. Sarcoma2022, 7949549 (2022).
   PubMedGoogle Scholar
• Rastogi S , AggarwalA, SotiKRet al. Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center. 35(Suppl. 15), 11064–11064 (2017).
   Google Scholar
• Italiano A , di MauroI, RappJet al. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study. Lancet Oncol.17(4), 532–538 (2016).
   PubMed Web of Science ®Google Scholar
• Gounder MM , AgaramNP, TrabuccoSEet al. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat. Commun.13(1), 1–15 (2022).
   PubMed Web of Science ®Google Scholar
• Spiro IJ , RosenbergAE, SpringfieldD, SuitH. Combined surgery and radiation therapy for limb preservation in soft tissue sarcoma of the extremity: the Massachusetts General Hospital experience. 13(1), 86–95 (2009).
   Google Scholar
• Tierney JF , AlvegårdTA, SigurdssonHet al. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst.Rev.2000(4), CD001419 (2000).
   Google Scholar
• Pervaiz N , ColterjohnN, FarrokhyarF, TozerR, FigueredoA, GhertM. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer113(3), 573–581 (2008).
   PubMed Web of Science ®Google Scholar
• Woll PJ , ReichardtP, le CesneAet al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol.13(10), 1045–1054 (2012).
   PubMed Web of Science ®Google Scholar
• Frustaci S , GherlinzoniF, de PaoliAet al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol.19(5), 1238–1247 (2001).
   PubMed Web of Science ®Google Scholar
• Gortzak E , AzzarelliA, BuesaJet al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur. J. Cancer37(9), 1096–1103 (2001).
   PubMed Web of Science ®Google Scholar
• Gronchi A , StacchiottiS, VerderioPet al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann. Oncol.27(12), 2283–2288 (2016).
   PubMed Web of Science ®Google Scholar
• Pasquali S , ColomboC, BottelliSet al. The Sarculator predicted risk of distant metastasis and overall survival in patients with high-risk soft tissue sarcoma treated with perioperative chemotherapy in a randomised controlled trial. Eur. J. Surg. Oncol.44(10), e2 (2018).
   Google Scholar
• Gronchi A , FerrariS, QuagliuoloVet al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol.18(6), 812–822 (2017).
   PubMed Web of Science ®Google Scholar
• Gronchi A , HindiN, CruzJet al. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): results of a phase I study in myxoid liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. EClinicalMedicine9, 35–43 (2019).
   PubMedGoogle Scholar
• Gronchi A , PalmeriniE, QuagliuoloVet al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG). 40(Suppl. 16), 11508–11508 (2022).
   Google Scholar
• Tanaka K , MachidaR, KawaiAet al. Results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306. J. Clin. Oncol.38(Suppl. 15), 11504–11504 (2020).
   Web of Science ®Google Scholar
• Palassini E , PizzamiglioS, PalmeriniEet al. A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): feasibility and activity of concurrent chemotherapy and radiation therapy. 41(Suppl. 16), 11506–11506 (2023).
   Google Scholar
• Gronchi A , VerderioP, DePaoli Aet al. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. Ann. Oncol.24(3), 817–823 (2013).
   PubMed Web of Science ®Google Scholar
• Palassini E , FerrariS, VerderioPet al. Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas randomized clinical trial: three versus five cycles of full-dose epirubicin plus ifosfamide. J. Clin. Oncol.33(31), 3628–3634 (2015).
   PubMed Web of Science ®Google Scholar
• Tanaka K , OgawaG, MizusawaJet al. Prospective comparison of various radiological response criteria and pathological response to preoperative chemotherapy and survival in operable high-grade soft tissue sarcomas in the Japan Clinical Oncology Group study JCOG0304. World J. Surg. Oncol.16(1), 162 (2018).
   PubMedGoogle Scholar
• Stacchiotti S , ColliniP, MessinaAet al. High-grade soft-tissue sarcomas: tumor response assessment–pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. 251(2), 447–456 (2009).
   Google Scholar
• Schuetze SM , RubinBP, VernonCet al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer103(2), 339–348 (2005).
   PubMed Web of Science ®Google Scholar
• Lim HJ , JohnnyOng CA, TanJWS, ChingTeo MC. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: a systematic review. Crit. Rev. Oncol. Hematol.143, 1–13 (2019).
   PubMed Web of Science ®Google Scholar
• Eilber FC , RosenG, EckardtJet al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol.19(13), 3203–3209 (2001).
   PubMed Web of Science ®Google Scholar
• Wardelmann E , HaasRL, BovéeJVMGet al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. Eur. J. Cancer53, 84–95 (2016).
   PubMed Web of Science ®Google Scholar
• Schaefer IM , HornickJL, BarysauskasCMet al. Histologic appearance after preoperative radiation therapy for soft tissue sarcoma: assessment of the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group Response Score. Int. J. Radiat. Oncol. Biol. Phys.98(2), 375–383 (2017).
   PubMed Web of Science ®Google Scholar
• Pasquali S , ColliniP, RomagosaCet al. Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): a planned analysis of the ISG-STS-1001 trial. 41(Suppl. 16), 11511–11511 (2023).
   Google Scholar
• Kawai A , YonemoriK, TakahashiS, ArakiN, UedaT. Systemic therapy for soft tissue sarcoma: proposals for the optimal use of pazopanib, trabectedin, and eribulin. Adv. Ther.34(7), 1556–1571 (2017).
   PubMed Web of Science ®Google Scholar
• Callegaro D , MiceliR, MarianiL, RautCP, GronchiA. Soft tissue sarcoma nomograms and their incorporation into practice. Cancer123(15), 2802–2820 (2017).
   PubMed Web of Science ®Google Scholar
• Jie Z , ZhiyingZ, LiL. A meta-analysis of Watson for Oncology in clinical application. Sci. Rep.11(1), 1–13 (2021).
   PubMed Web of Science ®Google Scholar
• Callegaro D , MiceliR, BonvalotSet al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol.17(5), 671–680 (2016).
   PubMed Web of Science ®Google Scholar
• Pasquali S , PizzamiglioS, TouatiNet al. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur. J. Cancer109, 51–60 (2019).
   PubMed Web of Science ®Google Scholar
• Pasquali S , PalmeriniE, QuagliuoloVet al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer128(1), 85–93 (2022).
   PubMed Web of Science ®Google Scholar
• Tawbi HA , BurgessM, BolejackVet al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol.18(11), 1493–1501 (2017).
   PubMed Web of Science ®Google Scholar
• Keung EZ-Y , NassifEF, LinHYet al. Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): survival results after 2years of follow-up and intratumoral B-cell receptor (BCR) correlates. 40(Suppl. 17), LBA11501–LBA11501 (2022).
   Google Scholar
• Mowery YM , BallmanKV, RiedelRFet al. SU2C–SARC032: a phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma. 36(Suppl. 15), TPS11588–TPS11588 (2018).
   Google Scholar
• Ronellenfitsch U , KarampinisI, Dimitrakopoulou-StraussAet al. Preoperative pazopanib in high-risk soft tissue sarcoma: phase II window-of opportunity study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04). Ann. Surg. Oncol.26(5), 1332–1339 (2019).
   PubMed Web of Science ®Google Scholar
• Wong P , HoughtonP, KirschDGet al. Combining targeted agents with modern radiotherapy in soft tissue sarcomas.. J Nate Cancer Inst.. 106(11), dju329 (2014).
   PubMedGoogle Scholar
• Weiss AR , ChenYL, ScharschmidtTJet al. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol.21(8), 1110–1122 (2020).
   PubMed Web of Science ®Google Scholar
• van Meekeren M , BoveeJVMG, van CoevordenFet al. A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. Acta Oncol. (Madr.)60(12), 1557–1564 (2021).
   PubMed Web of Science ®Google Scholar
• Kayton ML , WeissAR, XueWet al. Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): a report of major wound complications from the Children's Oncology Group and NRG Oncology. J. Surg. Oncol.127(5), 871–881 (2023).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN Clinical Practices Guidelines in Oncology, Soft Tissue Sarcomas, Version 2.2022. (2022).
   Google Scholar
• Gronchi A , MiahAB, DeiTos APet al. Federation; 25 Sarcomas and Rare Tumors Unit, IRCCS Regina Elena National Cancer Institute, Rome; 26 Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Departments of 70 Medical Oncology. Ann. Oncol.32, 1348–1365 (2021).
   PubMed Web of Science ®Google Scholar
• Rothermundt C , AndreouD, BlayJ-Yet al. Controversies in the management of patients with soft tissue sarcoma: recommendations of the Conference on State of Science in Sarcoma 2022. Eur. J. Cancer180, 158–179 (2023).
   PubMed Web of Science ®Google Scholar
• Liu Y , LiuC, ZhangH, YiX, YuA. Establishment of a nomogram for predicting the prognosis of soft tissue sarcoma based on seven glycolysis-related gene risk score. Front. Genet.12, 675865 (2021).
   PubMed Web of Science ®Google Scholar
• Crombé A , Spalato-CerusoM, MichotAet al. Gene expression profiling improves prognostication by nomogram in patients with soft-tissue sarcomas. Cancer Commun. (Lond.)42(6), 563–566 (2022).
   PubMed Web of Science ®Google Scholar
• Bertucci F , NiziersV, DeNonneville Aet al. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. J. Immunother. Cancer10(1), e003687 (2022).
   PubMed Web of Science ®Google Scholar
• Merry E , ThwayK, JonesRL, HuangPH. Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. NPJ Precis. Oncol.5(1), 17 (2021).
   PubMed Web of Science ®Google Scholar
• Salawu A , DemiccoE, ChungPWMet al. Circulating tumor DNA (ctDNA) detection of molecular residual disease (MRD) as a potential biomarker in localized soft tissue sarcoma (STS). 40(Suppl. 16), 11547–11547 (2022).
   Google Scholar
• Fuchs JW , SchulteBC, FuchsJR, AgulnikM. Targeted therapies for the treatment of soft tissue sarcoma. Front. Oncol.13, 1122508 (2023).
   PubMedGoogle Scholar
• Roulleaux Dugage M , NassifEF, ItalianoA, BahledaR. Improving immunotherapy efficacy in soft-tissue sarcomas: a biomarker driven and histotype tailored review. Front. Immunol.12, 775761 (2021).
   PubMed Web of Science ®Google Scholar